RU2408584C2 - Ингибиторы тирозинкиназы - Google Patents

Ингибиторы тирозинкиназы Download PDF

Info

Publication number
RU2408584C2
RU2408584C2 RU2008102381/04A RU2008102381A RU2408584C2 RU 2408584 C2 RU2408584 C2 RU 2408584C2 RU 2008102381/04 A RU2008102381/04 A RU 2008102381/04A RU 2008102381 A RU2008102381 A RU 2008102381A RU 2408584 C2 RU2408584 C2 RU 2408584C2
Authority
RU
Russia
Prior art keywords
benzo
pyridin
cyclohepta
methyl
oxo
Prior art date
Application number
RU2008102381/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2008102381A (ru
Inventor
Кристофер Дж. ДИНСМОР (US)
Кристофер Дж. ДИНСМОР
Джеймс П. ДЖЕВЕЛЛ (US)
Джеймс П. ДЖЕВЕЛЛ
Джейсон Д. КАТЦ (US)
Джейсон Д. КАТЦ
Мишелль Р. МАШАСЕК (US)
Мишелль Р. Машасек
Райан Д. ОТТЕ (US)
Райан Д. Отте
Джонатан Р. ЯНГ (US)
Джонатан Р. ЯНГ
Original Assignee
Мерк Шарп Энд Домэ Корп.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Шарп Энд Домэ Корп. filed Critical Мерк Шарп Энд Домэ Корп.
Publication of RU2008102381A publication Critical patent/RU2008102381A/ru
Application granted granted Critical
Publication of RU2408584C2 publication Critical patent/RU2408584C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
RU2008102381/04A 2005-06-23 2006-06-22 Ингибиторы тирозинкиназы RU2408584C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US69322905P 2005-06-23 2005-06-23
US60/693,229 2005-06-23
US72906105P 2005-10-21 2005-10-21
US60/729,061 2005-10-21
US60/789,473 2006-04-05

Publications (2)

Publication Number Publication Date
RU2008102381A RU2008102381A (ru) 2009-07-27
RU2408584C2 true RU2408584C2 (ru) 2011-01-10

Family

ID=37478833

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008102381/04A RU2408584C2 (ru) 2005-06-23 2006-06-22 Ингибиторы тирозинкиназы

Country Status (11)

Country Link
US (2) US8207186B2 (enExample)
EP (1) EP1896421B1 (enExample)
JP (2) JP4119478B1 (enExample)
AT (1) ATE524445T1 (enExample)
AU (1) AU2006262172B2 (enExample)
CA (1) CA2611530C (enExample)
DK (1) DK1896421T3 (enExample)
HR (1) HRP20110804T1 (enExample)
RU (1) RU2408584C2 (enExample)
SI (1) SI1896421T1 (enExample)
WO (1) WO2007002254A2 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013134398A1 (en) * 2012-03-06 2013-09-12 The Board Of Trustees Of The University Of Illinois Procaspase combination therapy for glioblastoma
US9399035B2 (en) 2012-03-06 2016-07-26 The Board Of Trustees Of The University Of Illinois Procaspase 3 activation by combination therapy
US9592229B2 (en) 2012-03-02 2017-03-14 The Board Of Trustees Of The University Of Illinois Potent anticancer activity via dual compound activation
US11510919B2 (en) 2017-11-17 2022-11-29 The Board Of Trustees Of The University Of Illinois Cancer therapy by degrading dual MEK signaling
US12090153B2 (en) 2018-10-05 2024-09-17 The Board Of Trustees Of The University Of Illinois Combination therapy for the treatment of uveal melanoma

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8207186B2 (en) 2005-06-23 2012-06-26 Merck Sharp & Dohme Corp. Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase MET
AU2006306496A1 (en) 2005-10-21 2007-05-03 Merck Sharp & Dohme Corp. Tyrosine kinase inhibitors
TW200813021A (en) * 2006-07-10 2008-03-16 Merck & Co Inc Tyrosine kinase inhibitors
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US8754094B2 (en) * 2007-08-15 2014-06-17 The Research Foundation Of State University Of New York Methods for heat shock protein dependent cancer treatment
US7893081B2 (en) 2007-12-20 2011-02-22 Merck & Co., Inc. Tyrosine kinase inhibitors
US9238571B2 (en) 2009-09-30 2016-01-19 Merck Sharp & Dohme Limited Formulations for c-Met kinase inhibitors
AU2010300930B2 (en) 2009-09-30 2014-09-11 Merck Sharp & Dohme (Uk) Limited Crystalline hydrochloride salts of c-MET kinase inhibitors
EA201290400A1 (ru) * 2009-11-30 2013-01-30 Протеолоджикс, Лтд. Малые производные пиримидина и способы их использования
CN101857594B (zh) * 2010-06-18 2013-04-03 南方医科大学 一种四氢吡啶并吲哚类化合物及其制备方法和应用
JP2013532627A (ja) 2010-07-01 2013-08-19 武田薬品工業株式会社 ｃＭＥＴ阻害剤とＨＧＦおよび／またはｃＭＥＴに対する抗体との組み合わせ
WO2013018733A1 (ja) 2011-07-29 2013-02-07 富士フイルム株式会社 １，５－ナフチリジン誘導体又はその塩
SG10201805807PA (en) 2012-06-26 2018-08-30 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
WO2014150996A1 (en) * 2013-03-15 2014-09-25 Cba Pharma, Inc. Cancer treatment
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
WO2016091891A1 (en) 2014-12-09 2016-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies against axl
US9375419B1 (en) * 2014-12-10 2016-06-28 Southern Research Institute Antiviral agents
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
US11129808B2 (en) 2016-03-15 2021-09-28 University Of South Florida PKC-delta-I inhibitor formulations and uses thereof
MX2021009863A (es) 2019-03-21 2021-11-12 Onxeo Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
US20230115865A1 (en) * 2019-10-01 2023-04-13 Sanofi Novel Substituted 6,7-Dihydro-5H-Benzo[7]Annulene Compounds, Processes for Their Preparation and Therapeutic Uses Thereof
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
KR20240115979A (ko) 2021-11-08 2024-07-26 프로젠토스 테라퓨틱스, 인크. 혈소판-유래 성장 인자 수용체(pdgfr) 알파 억제제 및 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2220139C2 (ru) * 1997-06-17 2003-12-27 Шеринг Корпорейшн Производные бензо(5,6)циклогепта(1,2-b)пиридина, фармацевтическая композиция на их основе и способы ингибирования аномального роста клеток и фарнезил-протеин-трансферазы

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL132137C (enExample) 1963-04-24
US4826853A (en) 1986-10-31 1989-05-02 Schering Corporation 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use
JP2852659B2 (ja) 1988-03-03 1999-02-03 富山化学工業株式会社 ピペラジン誘導体およびその塩
ZA914764B (en) 1990-06-22 1992-03-25 Schering Corp Bis-benzo or benzopyrido cyclohepta piperidene,piperidylidene and piperazine compounds,compositions and methods of use
US6365588B1 (en) 1993-10-15 2002-04-02 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
JP3847786B2 (ja) 1995-10-16 2006-11-22 協和醗酵工業株式会社 三環性化合物
BR9712819A (pt) 1996-09-13 1999-11-23 Schering Corp Compostos tricìclicos úteis para inibição de função de proteìna g e para tratamento de doenças proliferativas
AU4337597A (en) 1996-09-13 1998-04-02 Schering Corporation Substituted benzocycloheptapyridine useful as inhibitors of farnesyl-protein tr ansferase
US7018979B1 (en) * 2000-01-26 2006-03-28 Cedars-Sinai Medical Center Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor
JP2003523965A (ja) * 2000-01-26 2003-08-12 シーダース シナイ メディカル センター 異常な脳領域および／または悪性腫瘍に薬剤をデリバリーするためにカリウムチャンネルアゴニストを使用する方法
BR0212617A (pt) * 2001-09-19 2005-02-09 Pharmacia Corp Compostos de pirazolila substituìdo para o tratamento de inflamação
AU2003230758A1 (en) 2002-04-02 2003-10-20 Merck And Co., Inc. 5h-benzo(4,5)cyclohepta(1,2-b)pyridine nmda/nr2b antagonists
ES2211315B1 (es) 2002-11-12 2005-10-16 Almirall Prodesfarma, S.A. Nuevos compuestos triciclicos.
JP2006151809A (ja) 2002-12-26 2006-06-15 Ube Ind Ltd ベンゾシクロヘプタピリジン化合物
US8207186B2 (en) 2005-06-23 2012-06-26 Merck Sharp & Dohme Corp. Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase MET
AU2006306496A1 (en) 2005-10-21 2007-05-03 Merck Sharp & Dohme Corp. Tyrosine kinase inhibitors
AU2006306517A1 (en) 2005-10-21 2007-05-03 Merck Sharp & Dohme Corp. Tyrosine kinase inhibitors
EP1951252A4 (en) 2005-10-21 2010-03-17 Merck Sharp & Dohme TYROSINE KINASE INHIBITORS
TW200813021A (en) 2006-07-10 2008-03-16 Merck & Co Inc Tyrosine kinase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2220139C2 (ru) * 1997-06-17 2003-12-27 Шеринг Корпорейшн Производные бензо(5,6)циклогепта(1,2-b)пиридина, фармацевтическая композиция на их основе и способы ингибирования аномального роста клеток и фарнезил-протеин-трансферазы

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHRISTENSEN J G ET AL. A selective small molecule inhibitor of c-Met kinase inhibitors c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. CANCER RESEACH, AMERICAN ASSOCIATION FOR CANCER RESEACH, BALTIMORE, vol.63, no.21, p.7345-7355, 01.11.2003. *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9592229B2 (en) 2012-03-02 2017-03-14 The Board Of Trustees Of The University Of Illinois Potent anticancer activity via dual compound activation
US10874666B2 (en) 2012-03-06 2020-12-29 The Board Of Trustees Of The University Of Illinois Procaspase combination therapy for glioblastoma
US9421202B2 (en) 2012-03-06 2016-08-23 The Board Of Trustees Of The University Of Illinois Procaspase combination therapy for glioblastoma
US9399035B2 (en) 2012-03-06 2016-07-26 The Board Of Trustees Of The University Of Illinois Procaspase 3 activation by combination therapy
US10085977B2 (en) 2012-03-06 2018-10-02 The Board Of Trustees Of The Univerity Of Illinois Procaspase 3 activation by combination therapy
US10085978B2 (en) 2012-03-06 2018-10-02 The Board Of Trustees Of The University Of Illinois Procaspase combination therapy for glioblastoma
WO2013134398A1 (en) * 2012-03-06 2013-09-12 The Board Of Trustees Of The University Of Illinois Procaspase combination therapy for glioblastoma
US10888560B2 (en) 2012-03-06 2021-01-12 The Board Of Trustees Of The University Of Illinois Procaspase 3 activation by combination therapy
US11833147B2 (en) 2012-03-06 2023-12-05 Vanquish Oncology, Inc. Procaspase 3 activation by combination therapy
US11844798B2 (en) 2012-03-06 2023-12-19 The Board Of Trustees Of The University Of Illinois Procaspase combination therapy for glioblastoma
US12433885B2 (en) 2012-03-06 2025-10-07 The Board Of Trustees Of The University Of Illinois Procaspase combination therapy for glioblastoma
US11510919B2 (en) 2017-11-17 2022-11-29 The Board Of Trustees Of The University Of Illinois Cancer therapy by degrading dual MEK signaling
US12168006B2 (en) 2017-11-17 2024-12-17 The Board Of Trustees Of The University Of Illinois Cancer therapy by degrading dual MEK signaling
US12090153B2 (en) 2018-10-05 2024-09-17 The Board Of Trustees Of The University Of Illinois Combination therapy for the treatment of uveal melanoma

Also Published As

Publication number Publication date
WO2007002254A2 (en) 2007-01-04
ATE524445T1 (de) 2011-09-15
JP4119478B1 (ja) 2008-07-16
CA2611530A1 (en) 2007-01-04
JP5086762B2 (ja) 2012-11-28
EP1896421A2 (en) 2008-03-12
DK1896421T3 (da) 2012-01-09
AU2006262172B2 (en) 2010-05-27
SI1896421T1 (sl) 2012-01-31
RU2008102381A (ru) 2009-07-27
US20090197908A1 (en) 2009-08-06
JP2008156336A (ja) 2008-07-10
US8207186B2 (en) 2012-06-26
HRP20110804T1 (hr) 2011-11-30
CA2611530C (en) 2012-11-20
WO2007002254A3 (en) 2007-05-18
US7550478B2 (en) 2009-06-23
US20060293358A1 (en) 2006-12-28
EP1896421B1 (en) 2011-09-14
JP2008536877A (ja) 2008-09-11
AU2006262172A1 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
RU2408584C2 (ru) Ингибиторы тирозинкиназы
TWI543979B (zh) 可做為ａｔｒ酶抑制劑之化合物
ES2527567T3 (es) Inhibidores de la actividad de Akt
ES2497493T3 (es) Inhibidores de la tirosina quinasa
AU2007261440A1 (en) Tyrosine kinase inhibitors
EP3268003A1 (en) Thienopyrazine inhibitors of irak4 activity
CA2679694A1 (en) Inhibitors of janus kinases and/or 3-phosphoinositide-dependent protein kinase-1
EP1896422B1 (en) Tyrosine kinase inhibitors
CA2745165A1 (en) Inhibitors of phosphoinositide dependent kinase 1 (pdk1)
ES2370419T3 (es) Inhibidores de tirosina quinasa.
US7893081B2 (en) Tyrosine kinase inhibitors
HK1122271A (en) Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20120623